Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells.

<h4>Introduction</h4>Ataxia telangiectasia mutated and Rad3 Related (ATR) protein kinase is a key sensor of single-stranded DNA associated with stalled replication forks and repair intermediates generated during DNA repair. XRCC1 is a critical enzyme in single strand break repair and bas...

Full description

Bibliographic Details
Main Authors: Rebeka Sultana, Tarek Abdel-Fatah, Christina Perry, Paul Moseley, Nada Albarakti, Vivek Mohan, Claire Seedhouse, Stephen Chan, Srinivasan Madhusudan
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23451157/pdf/?tool=EBI
id doaj-3418478d6b2648b1a35627002ed8454a
record_format Article
spelling doaj-3418478d6b2648b1a35627002ed8454a2021-03-03T23:40:45ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0182e5709810.1371/journal.pone.0057098Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells.Rebeka SultanaTarek Abdel-FatahChristina PerryPaul MoseleyNada AlbaraktiVivek MohanClaire SeedhouseStephen ChanSrinivasan Madhusudan<h4>Introduction</h4>Ataxia telangiectasia mutated and Rad3 Related (ATR) protein kinase is a key sensor of single-stranded DNA associated with stalled replication forks and repair intermediates generated during DNA repair. XRCC1 is a critical enzyme in single strand break repair and base excision repair. XRCC1-LIG3 complex is also an important contributor to the ligation step of the nucleotide excision repair response.<h4>Methods</h4>In the current study, we investigated synthetic lethality in XRCC1 deficient and XRCC1 proficient Chinese Hamster ovary (CHO) and human ovarian cancer cells using ATR inhibitors (NU6027). In addition, we also investigated the ability of ATR inhibitors to potentiate cisplatin cytotoxicity in XRCC1 deficient and XRCC1 proficient CHO and human cancer cells. Clonogenic assays, alkaline COMET assays, γH2AX immunocytochemistry, FACS for cell cycle as well as FITC-annexin V flow cytometric analysis were performed.<h4>Results</h4>ATR inhibition is synthetically lethal in XRCC1 deficient cells as evidenced by increased cytotoxicity, accumulation of double strand DNA breaks, G2/M cell cycle arrest and increased apoptosis. Compared to cisplatin alone, combination of cisplatin and ATR inhibitor results in enhanced cytotoxicity in XRCC1 deficient cells compared to XRCC1 proficient cells.<h4>Conclusions</h4>Our data provides evidence that ATR inhibition is suitable for synthetic lethality application and cisplatin chemopotentiation in XRCC1 deficient ovarian cancer cells.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23451157/pdf/?tool=EBI
collection DOAJ
language English
format Article
sources DOAJ
author Rebeka Sultana
Tarek Abdel-Fatah
Christina Perry
Paul Moseley
Nada Albarakti
Vivek Mohan
Claire Seedhouse
Stephen Chan
Srinivasan Madhusudan
spellingShingle Rebeka Sultana
Tarek Abdel-Fatah
Christina Perry
Paul Moseley
Nada Albarakti
Vivek Mohan
Claire Seedhouse
Stephen Chan
Srinivasan Madhusudan
Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells.
PLoS ONE
author_facet Rebeka Sultana
Tarek Abdel-Fatah
Christina Perry
Paul Moseley
Nada Albarakti
Vivek Mohan
Claire Seedhouse
Stephen Chan
Srinivasan Madhusudan
author_sort Rebeka Sultana
title Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells.
title_short Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells.
title_full Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells.
title_fullStr Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells.
title_full_unstemmed Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells.
title_sort ataxia telangiectasia mutated and rad3 related (atr) protein kinase inhibition is synthetically lethal in xrcc1 deficient ovarian cancer cells.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2013-01-01
description <h4>Introduction</h4>Ataxia telangiectasia mutated and Rad3 Related (ATR) protein kinase is a key sensor of single-stranded DNA associated with stalled replication forks and repair intermediates generated during DNA repair. XRCC1 is a critical enzyme in single strand break repair and base excision repair. XRCC1-LIG3 complex is also an important contributor to the ligation step of the nucleotide excision repair response.<h4>Methods</h4>In the current study, we investigated synthetic lethality in XRCC1 deficient and XRCC1 proficient Chinese Hamster ovary (CHO) and human ovarian cancer cells using ATR inhibitors (NU6027). In addition, we also investigated the ability of ATR inhibitors to potentiate cisplatin cytotoxicity in XRCC1 deficient and XRCC1 proficient CHO and human cancer cells. Clonogenic assays, alkaline COMET assays, γH2AX immunocytochemistry, FACS for cell cycle as well as FITC-annexin V flow cytometric analysis were performed.<h4>Results</h4>ATR inhibition is synthetically lethal in XRCC1 deficient cells as evidenced by increased cytotoxicity, accumulation of double strand DNA breaks, G2/M cell cycle arrest and increased apoptosis. Compared to cisplatin alone, combination of cisplatin and ATR inhibitor results in enhanced cytotoxicity in XRCC1 deficient cells compared to XRCC1 proficient cells.<h4>Conclusions</h4>Our data provides evidence that ATR inhibition is suitable for synthetic lethality application and cisplatin chemopotentiation in XRCC1 deficient ovarian cancer cells.
url https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23451157/pdf/?tool=EBI
work_keys_str_mv AT rebekasultana ataxiatelangiectasiamutatedandrad3relatedatrproteinkinaseinhibitionissyntheticallylethalinxrcc1deficientovariancancercells
AT tarekabdelfatah ataxiatelangiectasiamutatedandrad3relatedatrproteinkinaseinhibitionissyntheticallylethalinxrcc1deficientovariancancercells
AT christinaperry ataxiatelangiectasiamutatedandrad3relatedatrproteinkinaseinhibitionissyntheticallylethalinxrcc1deficientovariancancercells
AT paulmoseley ataxiatelangiectasiamutatedandrad3relatedatrproteinkinaseinhibitionissyntheticallylethalinxrcc1deficientovariancancercells
AT nadaalbarakti ataxiatelangiectasiamutatedandrad3relatedatrproteinkinaseinhibitionissyntheticallylethalinxrcc1deficientovariancancercells
AT vivekmohan ataxiatelangiectasiamutatedandrad3relatedatrproteinkinaseinhibitionissyntheticallylethalinxrcc1deficientovariancancercells
AT claireseedhouse ataxiatelangiectasiamutatedandrad3relatedatrproteinkinaseinhibitionissyntheticallylethalinxrcc1deficientovariancancercells
AT stephenchan ataxiatelangiectasiamutatedandrad3relatedatrproteinkinaseinhibitionissyntheticallylethalinxrcc1deficientovariancancercells
AT srinivasanmadhusudan ataxiatelangiectasiamutatedandrad3relatedatrproteinkinaseinhibitionissyntheticallylethalinxrcc1deficientovariancancercells
_version_ 1714811257169641472